J. Jean Cui, Ph.D. Scientific Founder, President, and CEO

Dr. J. Jean Cui is the scientific founder, President, and CEO of BlossomHill Therapeutics. She was also the scientific founder and Chief Scientific Officer of Turning Point Therapeutics, Inc., an oncology biotech company that went public on NASDAQ in April 2019 (TPTX) and was subsequently acquired by Bristol Myers Squibb for $4.1 billion in August 2022. Prior to co-founding Turning Point, Dr. Cui served as a senior principal scientist and associate research fellow at Pfizer and held project and group leader roles at SUGEN, Inc., a Pharmacia Corporation. She is a lead inventor of three FDA-approved targeted cancer therapies: repotrectinib (AUGTYRO®), crizotinib (XALKORI®), and lorlatinib (LORBRENA®).

Jason Keyes, MBA Executive Vice President and Chief Financial Officer

Jason Keyes serves as the Executive Vice President and Chief Financial Officer of BlossomHill Therapeutics. Before joining BlossomHill, Mr. Keyes was the chief financial officer of Equillium, Inc. for over seven years, and also previously served as chief financial officer of Orexigen Therapeutics, Inc. His career spans nearly 25 years in the biotechnology industry, including various corporate finance and strategic planning positions at Amylin Pharmaceuticals, Inc., Amgen, Inc., and Baxter Healthcare Corporation. BlossomHill Therapeutics is a privately-held company supported by leading investors including Cormorant Asset Management, OrbiMed, and Vivo Capital.

Y. Peter Li, Ph.D., MBA Co-Founder and Executive Chairman

Dr. Y. Peter Li is a Co-Founder and the Executive Chairman of BlossomHill Therapeutics. He co-founded Turning Point Therapeutics, Inc. with Dr. J. Jean Cui, which was acquired by Bristol Myers Squibb for $4.1 billion in 2022.

Geoff Oxnard, M.D. Executive Vice President and Chief Medical Officer

Dr. Geoff Oxnard serves as the Executive Vice President and Chief Medical Officer of BlossomHill Therapeutics.

Vincent Liptak, J.D., Ph.D., MBA Executive Vice President and General Counsel

Dr. Vincent Liptak is the Executive Vice President and General Counsel of BlossomHill Therapeutics.

BlossomHill Therapeutics (BLSM) faces several key risks inherent to its nature as a clinical-stage biopharmaceutical company focused on oncology.

1. Clinical Development and Regulatory Approval Risk: As a clinical-stage company, BlossomHill's success is heavily contingent on its ability to successfully develop its product candidates through various clinical trial phases and ultimately secure regulatory approval. The company's lead candidate, BH-30643, is in a global Phase 1/2 clinical trial, while BH-30236 is in Phase 1, and BH-501284 is in the preclinical stage. There is no guarantee that any of these candidates will demonstrate sufficient safety and efficacy to gain approval from regulatory bodies like the FDA. The S-1 filing highlights that the field of precision medicine for genetically defined cancers is "rapidly evolving and scientifically uncertain," and the company's approach "may never lead to marketable products."
2. Intense Competition: BlossomHill operates in highly competitive oncology markets. Its lead product candidate, BH-30643, an OMNI-EGFR inhibitor for EGFR-mutant non-small cell lung cancer (NSCLC), is entering a field with established competitors such as AstraZeneca's Tagrisso and Johnson & Johnson's Rybrevant. Numerous other companies are also developing rival therapies for EGFR-mutant NSCLC. Similarly, its preclinical pan-KRAS inhibitor, BH-501284, faces competition from other companies further along in development, such as Revolution Medicines. This competition could limit market penetration and commercial success even if BlossomHill's products receive approval.
3. Funding and Commercialization Risk: As a development-stage company, BlossomHill Therapeutics does not currently generate product revenue and reported a net loss of $60.6 million in 2025. The company relies on external funding, such as its recent initial public offering (IPO), to finance its ongoing clinical trials and operations. Should BlossomHill's product candidates receive regulatory approval, the company would then face the significant challenge and cost of commercialization, including market acceptance, pricing, and securing reimbursement, without a prior track record of successful product launches. The S-1 filing also notes that "we may lack adequate funding to initiate or continue one or more of our clinical trials."

BlossomHill Therapeutics (BLSM) is a clinical-stage biopharmaceutical company focused on developing innovative small molecule medicines for cancer. The company's pipeline includes several product candidates targeting various cancers.

For its lead product candidate, BH-30643, an OMNI-EGFR inhibitor in a global Phase 1/2 trial for EGFR-mutant non-small cell lung cancer (NSCLC), the worldwide addressable market for EGFR medicines was approximately $8.0 billion in 2025 and is projected to exceed $13.4 billion by 2030.

Information regarding the specific addressable market sizes for BlossomHill's other main product candidates, BH-30236 (a CLK inhibitor for relapsed or refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS)) and BH-501284 (a preclinical pan-KRAS inhibitor), is not readily available in the provided search results.

BlossomHill Therapeutics (BLSM) is a clinical-stage biopharmaceutical company focused on developing innovative small molecule medicines for cancer treatment. As the company is currently in the clinical stage and has recently filed for an Initial Public Offering (IPO), its future revenue growth over the next 2-3 years will primarily be driven by the advancement and potential commercialization of its pipeline products.

The key expected drivers of future revenue growth for BlossomHill Therapeutics include:

1. Advancement and potential accelerated approval of BH-30643 in EGFR-mutant Non-Small Cell Lung Cancer (NSCLC): BH-30643, an OMNI-EGFR inhibitor, is BlossomHill's most advanced product candidate and is currently in a global Phase 1/2 clinical trial (SOLARA) for EGFR-mutant NSCLC. The company plans to seek an end-of-Phase 1 meeting with the FDA in the fourth quarter of 2026 to discuss recommended Phase 2 dosing and a potential accelerated approval pathway, particularly for patients with C797S-positive EGFR-mutant NSCLC, an area with significant unmet medical need. Dosing of the first patient in a pivotal Phase 2 trial is anticipated in the first quarter of 2027. The worldwide market for EGFR medicines was estimated at $8.0 billion in 2025 and is projected to exceed $13.4 billion by 2030, indicating a substantial market opportunity.
2. Progression of BH-30236 through clinical development for Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS): BH-30236, a CLK inhibitor, is currently undergoing a Phase 1 clinical trial in patients with relapsed or refractory AML and higher-risk MDS. Positive safety and efficacy data from this ongoing trial, expected to be reported in the first half of 2027, and its subsequent advancement into later-stage clinical trials, would be a significant driver for future revenue. The trial is evaluating BH-30236 as a monotherapy and in combination with venetoclax, the standard of care.
3. Initiation of clinical trials for BH-501284 (pan-KRAS inhibitor): BlossomHill also has a preclinical pan-KRAS inhibitor, BH-501284, which targets KRAS-driven cancers. The company intends to advance this preclinical asset into clinical testing in early 2027. Moving this candidate into the clinic would expand BlossomHill's pipeline into another significant oncology market, demonstrating pipeline progression and offering additional future revenue potential.

Share Issuance

• BlossomHill Therapeutics filed for an initial public offering (IPO) in July 2026, aiming to raise up to $100 million.
• The company plans to list its common stock on the Nasdaq Global Select Market under the symbol "BLSM."

Inbound Investments

• Since its founding in 2020, BlossomHill Therapeutics has raised over $257 million in private capital.
• In February 2024, the company had raised a total of $173 million from investors, including Colt Ventures, Cormorant Asset Management, and OrbiMed.
• An $84 million Series B extension financing round closed in December 2025, bringing the total capital raised to $257 million, with participation from new investors such as Janus Henderson Investors, Brahma Capital, and BioTrack Capital, alongside existing investors.

Capital Expenditures

• A portion of the net proceeds from the upcoming IPO is intended for capital expenditures, working capital, and other general corporate purposes.
• The company's San Diego, CA headquarters consists of approximately 46,300 sq ft of office and lab space, leased through 2035.
• The primary focus for capital allocation, including future capital expenditures, is to advance the clinical development of its drug candidates (BH-30643, BH-30236, and BH-501284).